CREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO
|
|
- Candace Berry
- 6 years ago
- Views:
Transcription
1 CREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO
2 STATE-OF-THE-ART GMP FACILITIES Our sites in Jena and Halle (Germany) provide a complete range of services for the development and GMP-compliant manufacture of biopharmaceuticals using microbial hosts. Two manufacturing lines with 300-liter and 1,500-liter fermentation vessels and corresponding DSP capacities are available to flexibly serve our clients. The proximity of Jena and Halle facilitates the exchange of know-how, and a team of approx. 200 experienced staff delivers superior customer service with tailor-made solutions. ESETEC and FOLDTEC are registered trademarks of Wacker Chemie AG. WACKER holds biomanufacturing certificates from the relevant authorities for both sites, and follows the ICH Q7A guidelines for GMPcompliant production of active pharmaceutical ingredients (APIs). Our quality systems are continuously assessed by a combination of internal, customer and official audits. The GMP production facility in Halle received EMA approval for commercial manufacturing in 2012 and U.S. FDA approval in The GMP facility in Jena has been approved by EMA in 2016.
3 A DEDICATED BIOLOGICS CONTRACT MANUFACTURER Wacker Biotech GmbH is THE MICROBIAL CMO the partner of choice for the contract manufacturing of therapeutic proteins in microbial systems. Integrated Service Portfolio WACKER s services cover molecular biology, process and analytical development, and the GMP manufacturing of biologics for clinical trials and commercial supply. We offer our customers added value with outstanding E. coli technologies that significantly increase the bioprocess efficiency and so reduce the cost of goods. From Scratch to Commercial Batch Wacker Biotech has an established track record and more than 20 years of experience in process design, process transfer and manufacturing of therapeutic proteins for a vast number of customers ranging from small biotechnology companies to big pharmaceutical corporates. Our experience covers all aspects from scratch to commercial batch, namely projects from preclinical development to drug substance delivery for commercial supply. We have completed more than 125 customer projects. More than 20 Years of Experience Founded in 1999 as a spin-off from the Hans-Knöll Institute in Jena, we have been a 100% subsidiary of Wacker Chemie AG since Biopharmaceutical manufacturing in Jena already started in the early nineties. In 2014, we rounded off our portfolio by acquiring Hallebased Scil Proteins Production GmbH.
4 EFFICIENT PROJECT MANAGEMENT Excellence in project management is key to the success of a project. For this reason, professional and dedicated project management is our top priority. Decades of experience in project management, know-how and efficient infrastructure are the basis for successful cooperation and for manufacturing products that meet the highest quality demands. Each project is unique and requires an individual approach. We are firmly focused on customer requirements and are sufficiently flexible to take on projects at any phase. We always work in close collaboration with our customers. Our work to achieve clearly defined and realistic targets is based on open and continuous communication. A dedicated project manager ensures focused and efficient project execution. Project managers are supported by teams of experts from the process development, quality control, quality assurance and production departments. For more information, please visit our website
5 CUTTING-EDGE TECHNOLOGIES Wacker Biotech offers innovative proprietary technologies for the efficient and cost-effective production of biologics: ESETEC : E. coli Secretion Technology WACKER s unique secretion system allows for high yields of correctly folded proteins in the culture broth. It comprises an engineered E. coli K12-based host strain, a set of proprietary plasmids, and a genetic toolbox to increase secretion. The technology has been successfully used for the production of a broad variety of recombinant proteins, including therapeutic Fabs, scaffolds and single domain antibodies with yields up to 14g/L. With straightforward strain and process development and 3 times lower COGS, ESETEC is a costand time-efficient alternative for mammalian systems. FOLDTEC : E. coli Folding Technology While WACKER s own ESETEC technology has proven highly efficient in producing soluble proteins via secretion, poorly soluble substances form aggregated inclusion bodies within the cell. Here protein refolding is a key production stage in order to achieve the desired active properties. The FOLDTEC technology is based on proprietary E. coli strains optimized for high-quality inclusion bodies and superior yields (up to 12 grams per liter). Complemented by our years of experience in refolding and a tailored screening approach, FOLDTEC offers better efficacies, smaller folding volumes and fully scalable manufacturing processes without the need for antibiotics or undesired phage components. In synergy with WACKER s high-cell-density fermentation systems, FOLDTEC provides unique solutions for the sophisticated manufacturing of biopharmaceuticals by refolding. PASylation : Innovative Technology for Extension of Plasma Half-Life In collaboration with the German company XL-protein GmbH, WACKER offers the production of PASylated biopharmaceuticals using ESETEC. Recently, PASylated Fabs were produced with yields > 4 g/l.
6 The data presented in this medium are in accordance with the present state of our knowledge but do not absolve the user from carefully checking all supplies immediately on receipt. We reserve the right to alter product constants within the scope of technical progress or new developments. The recommendations made in this medium should be checked by preliminary trials because of conditions during processing over which we have no control, especially where other companies raw materials are also being used. The information provided by us does not absolve the user from the obligation of investigating the possibility of infringement of third parties rights and, if necessary, clarifying the position. Recommendations for use do not constitute a warranty, either express or implied, of the fitness or suitability of the product for a particular purpose. 7093e/07.17 replaces 7093e/05.17 Wacker Biotech GmbH Jena and Halle, Germany Tel info.biologics@wacker.com
Advanced Microbial Protein Expression
Advanced Microbial Protein Expression Partners for Life Advancing tomorrow s medicines w A Biologics and Vaccines CDMO partner for your complete clinical journey Good science, experience and a quality
More informationDifferentiated by Innovation & Growth Dr. Gerhard Schmid, President WACKER BIOSOLUTIONS December 3 rd, 2018
CREATING TOMORROW`S SOLUTIONS Differentiated by Innovation & Growth Dr. Gerhard Schmid, President December 3 rd, 2018 0 Disclaimer The information contained in this presentation is for background purposes
More informationPRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.
More informationPRELIMINARY AGENDA ** Attendees must already be registered to attend cphi Japan conference**
PRELIMINARY AGENDA ** Attendees must already be registered to attend cphi Japan conference** The Future of Biologics Development and Manufacturing 20 April 2017 13:00 16:00 Big Sight Exhibition Center,
More informationLFB BIOMANUFACTURING YOUR CDMO PARTNER FOR MABS AND RECOMBINANT PROTEINS B IOMANUFACTURING
YOUR CDMO PARTNER FOR MABS AND RECOMBINANT PROTEINS B IOMANUFACTURING COMMITMENT AND FLEXIBILITY LFB BIOMANUFACTURING is a medium-sized CDMO offering Bioproduction services, from an industrial facility
More informationA catalyst that satisfiess the most sophisticated demands while meeting ecological standards? A catalyst that already
CREATING TOMORROW S SOLUTIONS ELASTOMERS & PLASTICS I TIN-FREE MOLDMAKING Form has no limits TIN-FREE SYSTEM NEO FOR CONDENSATION CURING MAKE YOUR MOLDMAKING MORE ECOLOGICAL: ELASTOSIL TIN-FREE SYSTEM
More informationFRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS
FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS Close-up of large scale UF/DF control unit conditions and
More informationPharma&Biotech. XS Microbial Expression Technologies Optimize Productivity, Speed and Process Robustness
Pharma&Biotech XS Microbial Expression Technologies Optimize Productivity, Speed and Process Robustness Embracing Complexity Based on 30 years of innovation in microbial biotechnology, Lonza offers the
More informationVINNAPAS 4220 L: THE PERFECT MULTI-TALENT FOR ECONOMIC FLOORING APPLICATIONS
CREATING TOMORROW S SOLUTIONS CONSTRUCTION I DISPERSIBLE POLYMER POWDERS I EMEA 4220 L: THE PERFECT MULTI-TALENT FOR ECONOMIC FLOORING APPLICATIONS 4220 L: GREAT OVERALL PERFORMANCE 4220 L shows superior
More informationCONTRACTING CELL CULTURE
CONTRACTING CELL CULTURE BIOTECH EXPERIENCE Page 2 Professionals in proteins and antibodies Bayer HealthCare has more than 130 years of experience in developing and producing pharmaceuticals. An integral
More informationTable of Contents. Presented by
Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com May 2017 TABLE OF CONTENTS
More informationSynCo Bio Partners B.V. & Wacker Biotech GmbH: THE MICROBIAL CMO
CREATING TOMORROW`S SOLUTIONS SynCo Bio Partners B.V. & Wacker Biotech GmbH: THE MICROBIAL CMO Human Microbiota: Proof of Concept to Production Işil Tüzün Weber Process Engineer Technical Operations Title
More informationSandoz Biopharmaceuticals. Sandoz Biosimilars. Quality, Heritage and Excellence through Novartis Manufacturing
Sandoz Biopharmaceuticals Sandoz Biosimilars Quality, Heritage and Excellence through Novartis Manufacturing 2 SANDOZ BIOPHARMACEUTICALS High-quality biologics manufacturing at Novartis Biologics, including
More informationBiotechpharma company profile. Romanas Ramanauskas Business development manager
Biotechpharma company profile Romanas Ramanauskas Business manager October, 2012 1 Contents History Company overview Services and capabilities Expression system and process Technology scale-up and GMP
More informationOverview Rentschler Biotechnologie
Overview Rentschler Biotechnologie AusBiotech, Adelaide, 18.10.2011 Klaus B. Schoepe, PhD, SVP Client Relations - 1 - Our Mission As an independent leading, internationally operating service company, we
More informationINTEGRATED PRODUCTION PLATFORMS
FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME PROCESS DEVELOPMENT, SCALE UP, GMP-COMPLIANT PRODUCTION AND CONSULTING INTEGRATED PRODUCTION PLATFORMS EVERYTHING STARTS WITH YOUR BRILLIANT
More informationWACKER BIOSOLUTIONS - A Breeding Ground For Innovation And Growth
CREATING TOMORROW`S SOLUTIONS WACKER BIOSOLUTIONS - A Breeding Ground For Innovation And Growth Dr. Thomas Maier, Managing Director WACKER Biotech GmbH 0 of 17 Disclaimer The information contained in this
More informationPlant Made Biopharmaceuticals NEXT-GENERATION THERAPEUTICS FOR ORPHAN DISEASES
Plant Made Biopharmaceuticals NEXT-GENERATION THERAPEUTICS FOR ORPHAN DISEASES PLANT MADE BIOPHARMACEUTICALS: OUR ASSET, YOUR ADVANTAGE We at Greenovation work to advance the development of new treatments
More informationHighTech Business Decisions August 2016
Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222 San Jose, California 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com August 2016 TABLE OF CONTENTS Chapter
More informationWe make drugs smarter
We make drugs smarter Brookwood Pharmaceutical Services WE MAKE DRUGS SMARTER Using our 40 years of experience, our state of the art facilities and our IP protected technologies, we leverage existing capabilities
More informationEvonik Birmingham Laboratories
Evonik Birmingham Laboratories An integrated CDMO for advanced parenterals with a portfolio of delivery technologies, formulation development services and GMP manufacturing Evonik Birmingham Laboratories
More informationTABLE OF CONTENTS. 1.3 Industry Pricing Trends Recent Industry Pricing Changes Contractor Utilization Rates 1-5
TABLE OF CONTENTS Chapter 1: EXECUTIVE SUMMARY 1.1 Introduction 1-1 1.2 Participants Locations 1-3 1.3 Industry Pricing Trends 1-4 1.3.1 Recent Industry Pricing Changes 1-4 1.3.2 Contractor Utilization
More informationCREATING TOMORROW S SOLUTIONS FOR EFFICIENT BONDING PASTES ONE GRADE BETTER: HDK H18
CREATING TOMORROW S SOLUTIONS ADHESIVES I Pyrogenic Silica FOR EFFICIENT BONDING PASTES ONE GRADE BETTER: HDK H18 HDK H18 THE BEST GRADE FOR EFFICIENCY 2 To meet the demand for higher energy yields from
More informationTable of Contents. Welcome to Dishman. Our Mission. Our Focus: Client Satisfaction
Welcome to Dishman Our Mission Dishman Group continually invests in the global pharmaceutical industry, ensuring Dishman s business can provide pharmaceutical customers with high-value, high-quality products
More informationWacker Chemie AG Industry meets Start-ups
CREATING TOMORROW`S SOLUTIONS Dr. Thomas Renner 0 of 9 WACKER s Innovations Are Based on Internal R&D Activities and Enhanced via Collaborations Innovation Strategy Innovation Management: Project system
More informationFast Trak Services: a collaborative project to accelerate downstream biosimilar process development
GE Healthcare Fast Trak Services: a collaborative project to accelerate downstream biosimilar process development A case study Case study, 2924332 AA Fast Trak Services A collaborative project to accelerate
More informationTom Sulpizio and Jeff Taniguchi, Advanced Minerals Corporation A Member of Imerys 130 Castilian Way, Santa Barbara, CA 93117
ADVANCES IN DISPOSABLE DIATOMITE FILTER AID SYSTEMS FOR CGMP BIOSEPARATIONS Session Pretreatment in Bioseparations AFSS Annual Meeting Valley Forge, PA May 20, 2008 ABSTRACT Tom Sulpizio and Jeff Taniguchi,
More informationDSM Biologics. DSM Brings Mammalian cgmp Manufacturing to Australia
DSM Biologics AusBioTech 2012 Melbourne October 31, 2012 Marc Goemans VP Global Marketing & Sales DSM Brings Mammalian cgmp Manufacturing to Australia Agenda Introduction Brisbane How do we serve Australian
More informationLONG R3IGF-I: An Insulin Alternative Exclusively for Cell Culture Applications
Page 1 of 5 Page 1 of 5 Return to Web Version LONG R3IGF-I: An Insulin Alternative Exclusively for Cell Culture Applications By: Jennifer Fries, BioFiles 2009, 4.5, 14. LONG R 3 IGF-I is a recombinant
More informationEden Biodesign ebook. Celebrating 10 Years of Success
Eden Biodesign ebook Celebrating 10 Years of Success Eden Biodesign ebook Chapter 1: Overview Chapter 2: Our History Chapter 3: Much More than a CMO Chapter 4: Key Milestones Chapter 5: About Eden Biodesign
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationSandoz Biopharmaceuticals. Sandoz Biosimilars. More than a decade of experience
Sandoz Biopharmaceuticals Sandoz Biosimilars More than a decade of experience 2 SANDOZ BIOPHARMACEUTICALS The pioneer and global leader in biosimilars Repeatedly innovating to break new ground 2006 Launched
More informationMDI Manufacturing Services
MDI Manufacturing Services Presenter, Date Who we are 3M Drug Delivery Systems is a division of 3M dedicated to working together with pharmaceutical and biotech companies to bring new and improved products
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationWhere science turns into products
Where science turns into products Etanercept Factor VIII Parathyroid Hormone Interferon Alfa-2a Interferon Alfa-2b Peg-Interferon Alfa-2b Interferon Beta-1a Interferon Beta-1b Erythropoietin Filgrastim
More informationGenes to Proteins to Antibodies
Genes to Proteins to Antibodies About Us Fusion Antibodies is a CRO established in 2001 as a spin-out from Queen s University Belfast. The company building is situated in a charming area of Springbank
More informationHarmonized Quality Requirements for Biotech Investigational Medicinal Products - A Regulator's View
Harmonized Quality Requirements for Biotech Investigational Medicinal Products - A Regulator's View Brigitte Brake Pharmaceutical Biotechnology BfArM, Bonn Evaluation Criteria National vs. EU Clinical
More informationDebendra K. Sahoo INSTITUTE OF MICROBIAL TECHNOLOGY CHANDIGARH
Thursday 5 November EU-India PARTNERING EVENT Theme: Life sciences, biotechnology and biochemistry for sustainable non-food products and processes IMTECH Debendra K. Sahoo INSTITUTE OF MICROBIAL TECHNOLOGY
More informationBD Resurge Media Supplements Chemically Defined. Protein Free. Animal Free.
D Resurge Media Supplements Chemically Defined. Protein Free. nimal Free. Overview Cell-based production of active pharmaceutical ingredients generally requires supplementation of cell culture media to
More informationYour bridge to. better medicines
Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)
More informationibio, Inc. Holds Annual Meeting in College Station, Texas
April 7, 2016 ibio, Inc. Holds Annual Meeting in College Station, Texas NEW YORK, NY -- (Marketwired) -- 04/07/16 -- ibio, Inc. (NYSE MKT: IBIO) - Speaking to shareholders at the ibio, Inc. (NYSE MKT:
More informationThermo Scientific Nucleic Acid Technologies
Thermo Scientific Nucleic Acid Technologies Phosphoramidites for Oligonucleotide Synthesis High Purity Nucleotides and Polynucleotides Fluorescent Labeling and Detection Custom Chemistries Molecular Biology
More informationSCIENTIFIC. Process for Success. CHO ONE Media System. Expression Media for Fed-Batch Culture
CAPRICORN SCIENTIFIC Process for Success CHO ONE Media System Expression Media for Fed-Batch Culture Culture for Life www.capricorn-scientific.com 2 Capricorn Scientific as a young established cell culture
More informationCorporate. Established in Acquired facilities of: Competencies across the Generics & Biologics, value chain.
Established in 2013 Acquired facilities of: Corporate Enzon Pharmaceuticals- NJ, USA- 2013 Pfizer- NY, USA- 2016 Competencies across the Generics & Biologics, value chain. Contract Manufacturing Fully
More informationRE: Draft Annex 2: Manufacture of Biological Medicinal Products for Human Use
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 14 March 2008 European Commission Enterprise and Industry Directorate-General B-1049 Brussels Belgium BY EMAIL TO entr-gmp@ec.ec.europa.eu
More informationLAB EXPERTS AT YOUR SIDE Over twenty years of experience
LAB EXPERTS AT YOUR SIDE Over twenty years of experience About us SYNLAB Pharma offers a broad range of laboratory services to the biotechnology, pharmaceutical and cosmetic industries as well as to manufacturers
More informationEuropean Contract Biomanufacturing Organizations CbMO Market Outlook
European Contract Biomanufacturing Organizations CbMO Market Outlook Date: 9/3/2011 By Philippe Tramoy, Claude Bensoussan Copyright 2011 CBDM.T SARL. All rights reserved. Any unauthorized use or disclosure
More informationPharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA
Pharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA 1 2 ND MENA Regulatory Conference On Bioequivalence, Biowaivers, Bioanalysis, Dissolution & Biosimilars
More informationCOMPANY PROFILE. Dishman offers innovation, security of supply and value for money. Dishman Group. Research EARLY STAGE API. Preclinical.
COMPANY PROFILE Dishman is a global outsourcing partner for the pharmaceutical industry offering a portfolio of development, scale-up and services. Dishman improves its customers businesses by providing
More informationRegulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationPlant Made Biopharmaceuticals NEXT-GENERATION THERAPEUTICS FOR ORPHAN DISEASES
Plant Made Biopharmaceuticals NEXT-GENERATION THERAPEUTICS FOR ORPHAN DISEASES BryoTechnology: enables delivery of a wide range of products customized according to the individual needs of our clients 02
More informationICH Q11 Development & manufacture of drug substances
ICH Q11 Development & manufacture of drug substances Keith McDonald Group Manager Medicines & Healthcare products Regulatory Agency (UK) 2011 ICH International Conference on Harmonisation of Technical
More informationAbout Us. What We Do and Who We Are. Company. Management
About Us What We Do and Who We Are Company Management ProJect Pharmaceutics transforms all kinds of chemical and biological ingredients into pioneering drugs. We are experts in formulation science and
More informationThe Elite Provider. Cell & Gene. Therapy Manufacturing
The Elite Provider Cell & Gene Therapy Manufacturing GMP Manufacturing Services The cgmp manufacturing in Vigene is compliant with US FDA and EU EMA regulatory requirements. The manufacturing area consists
More informationSartorius Stedim Cellca. Custom Cell Line & Process Development for Pharmaceutical Purposes
Sartorius Stedim Cellca Custom Cell Line & Process Development for Pharmaceutical Purposes May 2017 Overview of Contents 1 2 3 Cellca History Overview: Cellca Technology Platform Products & Services 4
More informationNational Institute of Immunology, New Delhi
National Institute of Immunology, New Delhi QUOTATION INVITATION NOTICE For Website Ref: NII/AKS/GPL/2013 Date: 25/12/2013 Quotations are invited from technical firms specializing in either both or one
More informationFusion Antibodies. Genes to Proteins to Antibodies
Fusion Antibodies Genes to Proteins to Antibodies Why Fusion Antibodies? 12 years experience of Antibody drug development Milestoned Payments European based limited company High Quality outcomes for the
More informationManufacturing Integrated Biologics Manufacturing
Manufacturing Integrated Biologics Manufacturing Integrated Biologics Manufacturing Abzena provides customer focused process development and manufacturing services for cgmp and non-gmp production of recombinant
More informationFujifilm Diosynth Biotechnologies. General Introduction
Fujifilm Diosynth Biotechnologies General Introduction October 2016 Value from Innovation Safety information Accompanied by FDB staff at all times Fire alarm. Follow host to assembly point Toxic alarm.
More informationPotelligent CHOK1SV. How It Works. Potelligent CHOK1SV
Potelligent CHOK1SV Potelligent CHOK1SV Potelligent CHOK1SV How It Works A new host cell line for the production of recombinant antibodies has been developed through close collaboration between Lonza and
More informationto acquire Investor And Analyst Call Presentation January 4, 2008
to acquire Investor And Analyst Call Presentation January 4, 2008 Safe Harbor Statement The following information contains, or may be deemed to contain, forward looking statements (as defined in the U.S.
More informationNaNoplasmid TM. Platform SIZE MATTERS SMALLER IS BETTER
Nanoplasmid TM Platform NaNoplasmid TM The Nanoplasmid is a dramatically improved Key Cassette (
More informationIndia as an Outsourcing Frontier in Biotechnology
1 India as an Outsourcing Frontier in Biotechnology K.V. Subramaniam President & CEO 3 rd Annual Biotech Supply Chain Academy Conference San Francisco Oct 26, 2010 Biotechnology Industry Issues Long gestation
More informationCREATING TOMORROW S SOLUTIONS CONSTRUCTION I POLYMER DISPERSIONS I EMEA PRODUCT OVERVIEW POLYMER DISPERSIONS
CREATING TOMORROW S SOLUTIONS CONSTRUCTION I POLYMER DISPERSIONS I EMEA PRODUCT OVERVIEW POLYMER DISPERSIONS POLYMER CHEMISTRY A KEY TO QUALITY Polymer binders enhance two critical characteristics of all
More informationProduct lifecycle management in one site
Product lifecycle management in one site Today s world provides multiple opportunities for a biopharma company. An aging global population and the prevalence of chronic and communicable diseases are creating
More informationCONTRACT RESEARCH SERVICES
1537 NW 65th Avenue Plantation, FL 33313 USA Phone: (954) 321-8988 Fax: (954) 321-9778 info@receptopharm.com www.receptopharm.com ReceptoPharm has installed the pathways to develop, produce and supply
More informationThe Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics
The Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics Visit of Alabama Biotech Oct 2014 Alain BERNARD Vice President GPS, UCB Technical Operations Tech Ops BioTech
More informationIntroduction of Development Center for Biotechnology TAIWAN
Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394
More informationInvestor Presentation. September 2018
Investor Presentation September 2018 Safe Harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties
More informationEmpowering innovation.
Empowering innovation. RESOMER is a synonym for innovation and vision, enabling both pharma and medical device companies to shape and design a better future. 30 years of RESOMER The history of RESOMER
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 15 July 2010 European Commission Enterprise and Industry Directorate General Consumer Goods, Pharmaceuticals B-1049 Brussels
More informationSwitzerland EXPERTS TAKING CARE
CordenPharma Switzerland EXPERTS TAKING CARE CordenPharma Switzerland Eichenweg 1 4410 Liestal Switzerland Phone +41 61 906 59 59 Fax +41 61 906 59 58 sales@cordenpharma.com www.cordenpharma.com Our History
More informationEthylene gives permanent flexibility to the VAE polymer. No external plasticizer is thus necessary in VAEs.
CREATING TMRRW S SLUTINS ADHESIVES I PLYMER BINDERS I North America Product verview VINNAPAS AND VINNL Dispersions MAKE THE MVE T VINNAPAS VAE: The High-Performance solution Success in the adhesives market
More informationDriving Value through Innovation in Biotech Manufacturing. Agenda
Driving Value through Innovation in Biotech Manufacturing Jorg Thommes, PhD Senior Vice President Operations Technology and Innovation Biogen 7 October 2015 Agenda Biopharma Legacy, Trends, & Challenges
More informationQuality & Safety GLP. 44 q&more 02/14
Quality & Safety GLP 44 q&more 02/14 More than keeping a lab notebook GLP regulations and their new role in the approval of medicines for advanced therapies (ATMPs) Dr Katja Schellenberg, Translation Centre
More informationKnow-how and Best Practice to Serve our Clients
BioChem Analytical Laboratory Know-how and Best Practice to Serve our Clients BioChem Analytical Laboratory Leading in all Disciplines One laboratory, three disciplines: Everything under one roof - competent,
More informationVince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016
Quality Management in a Virtual Environment Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Biosimilars - the second wave of biotech -an evolving regulatory
More informationInvestor presentation. December 2018
Investor presentation December 2018 Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties
More informationYour Protein Manufacturer
Expression of Toxic Proteins in E. coli Your Protein Manufacturer Contents 1. Definition of Toxic Protein 2. Mechanisms of Protein Toxicity 3. Percentage of Protein Toxicity 4. Phenotypes of Protein Toxicity
More informationVetter Development Service
A unique blend of expertise for clinical manufacturing Vetter Development Service Supporting your compound s success Answers that work 1 Your molecule s future starts here. By the time your new injectable
More informationBiologics. Biologics. The Centre for Process Innovation. From innovation to commercialisation
Biologics Biologics The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The High Value Manufacturing Catapult is
More informationThe Complete Solution: Althea s Simplified ADC Supply Chain
The Complete Solution: Althea s Simplified ADC Supply Chain You have the power to make a difference. To make new therapeutics that improve quality of life and inspire a healthier world. To do this, you
More informationDrug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel
Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active
More informationOptimization Strategies of Expression Cell Line Construction to Reduce the Biological Drug Development Risk. Feng Gao, MD, PhD. AutekBio CO.
Optimization Strategies of Expression Cell Line Construction to Reduce the Biological Drug Development Risk Feng Gao, MD, PhD AutekBio CO. Expression Systems used for Approved Antibody and Antibody-Related
More informationCREATING TOMORROW S SOLUTIONS CONSTRUCTION I POLYMER POWDERS I MEA PRODUCT OVERVIEW VINNAPAS DISPERSIBLE POLYMER POWDERS
CREATING TOMORROW S SOLUTIONS CONSTRUCTION I POLYMER POWDERS I MEA PRODUCT OVERVIEW VINNAPAS DISPERSIBLE POLYMER POWDERS THE FAST TRACK PRODUCT FINDER Grade Typical General Properties Recommended Applications*
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationPharmabiotics: a Regulatory Hurdle in Europe
Pharmabiotics: a Regulatory Hurdle in Europe Dr. Magali Cordaillat-Simmons PRI Executive Scientist Raleigh, NC, USA September 8th, 2014 PHARMABIOTICS: A REGULATORY HURDLE IN EUROPE I. Introduction to Pharmabiotics
More informationCREATING TOMORROW S SOLUTIONS MOBILITY. e-novation FOR FUEL CELLS POWERED BY SILICONES
CREATING TOMORROW S SOLUTIONS MOBILITY e-novation FOR FUEL CELLS POWERED BY SILICONES PUTTING FUEL CELLS IN THE FAST LANE A fuel-cell vehicle (FCV) or fuel-cell electric vehicle (FCEV) is an electric vehicle
More informationQ&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document
Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document March 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 ICH Q7 - Questions
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationTrends in capacity utilization for therapeutic monoclonal antibody production
[mabs 1:2, 151-156; March/April 2009]; 2009 Landes Bioscience Report Trends in capacity utilization for therapeutic monoclonal antibody production Eric S. Langer President and Managing Partner; BioPlan
More informationEMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016
EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems Jan Thomsen Warsaw, November 15 th, 2016 2 Content Emprove - An Introduction Emprove for Raw and Starting Materials
More informationExpression of Next Generation Biologics Requires Next Generation Expression Systems
Expression of Next Generation Biologics Requires Next Generation Expression Systems Joachim Klein, Ph.D., Associate Director, Head of Strain Development and Cell Banking Georg Blaser, Ph.D., Associate
More informationSynthetic vaccine research and development. Comprehensive and innovative synthetic biology solutions and technologies
Synthetic vaccine research and development Comprehensive and innovative synthetic biology solutions and technologies From plan to product, Thermo Fisher Scientific supports your synthetic vaccine goals
More informationOur passion is to deliver sustainable value to our customers Business Update: Third Quarter October 2007
Our passion is to deliver sustainable value to our customers Business Update: Third Quarter 23 October Stefan Borgas Chief Executive Officer Disclaimer Certain matters discussed in this presentation may
More informationCREATING TOMORROW S SOLUTIONS ARCHITECTURAL COATINGS I POLYMER DISPERSIONS I SOUTH AMERICA PRODUCT OVERVIEW
CREATING TOMORROW S SOLUTIONS ARCHITECTURAL COATINGS I POLYMER DISPERSIONS I SOUTH AMERICA PRODUCT OVERVIEW POLYMER CHEMISTRY A KEY TO QUALITY Polymer binders enhance two critical characteristics of all
More informationAnalytical Method Validation
National University of Singapore Academy of GxP Excellence (NUSAGE) & PharmEng Technology Presents Part of the Pharmaceutical and Biotechnology Training Courses Instructor LOH Kean Chong, Ph.D.* Senior
More informationRecent Opportunities & Challenges in microbial manufacturing
Recent Opportunities & Challenges in microbial manufacturing Elise Mous, CPhI Frankfurt, Oct 24 2017 Industry trend & challenge Customer perspective on outsourcing Key trend: Overall outsourcing growth
More informationCREATING TOMORROW S SOLUTIONS CONSTRUCTION AND PAINTS I POLYMER DISPERSIONS I WESTERN EUROPE PRODUCT OVERVIEW POLYMER DISPERSIONS
CREATING TOMORROW S SOLUTIONS CONSTRUCTION AND PAINTS I POLYMER DISPERSIONS I WESTERN EUROPE PRODUCT OVERVIEW POLYMER DISPERSIONS POLYMER CHEMISTRY A KEY TO QUALITY Polymer binders enhance two critical
More informationPatricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, (732)
Pharmaceutical Technology Patricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, pvanarnum@advanstar.com, (732) 346-3072 Biopharmaceutical Industry in 2012: Optimism on the Rise
More information